Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Table 3 Base-case results

Charity assistance	Chemotherapy alone	Durvalumab plus chemotherapy
Charity assistance		Yes	No
Cost ($)	16,667.75	35,222.94	97,628.84
Incremental cost ($)		18,555.19	80,961.10
QALYs	1.68	1.80
Incremental QALYs		0.12
ICER($/QALY)		159,644.70	696,571.11

ISSN: 1478-7547